Key Drivers
- Strong margins
- Solid cash flow
- High leverage
AIAI Summary
HAE is shifting from a steady medtech compounder to a turnaround story where strong plasma and blood management growth plus healthy free cash flow support the case, but the stock now hinges on Interventional Technologies stabilizing—without that, the premium valuation and recent rally remain vulnerable.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong margins
- •Solid cash flow
- •High leverage
HAE looks fundamentally solid on a full-year basis with strong margins, cash flow, and liquidity, but high leverage, a heavy intangible asset base, a recent quarterly loss, and a pricey valuation make the stock a mixed-risk setup.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Cooling momentum
- •Breakout resistance
Over the last month, HAE remains constructive after climbing from $65.88 to $75.07, but momentum has cooled into a likely consolidation below $77.6 with near-term support around $74.8-$75.1 and key downside risk if $72.5 breaks.
Rapid run-up left the stock briefly overbought, then it pulled back into consolidation
Sentiment & News
Key News Insights:
- •Segment Restructure
- •Share Momentum
- •Debt Pressure
Haemonetics' segment restructure, conference visibility, and recent share gains point to improving sentiment, but debt and competitive pressure remain meaningful headwinds amid broader HAE-sector news.
The news is modestly positive for the instrument, as operational clarity and supportive market action outweigh near-term leverage and competition concerns
Similar Companies in Healthcare
Other companies in the same sector with AI ratings